Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Fungus
Reexamination Certificate
2007-07-03
2007-07-03
Gitomer, Ralph (Department: 1655)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Fungus
C435S254100
Reexamination Certificate
active
10354537
ABSTRACT:
Methods are disclosed for using red rice fermentation products for the treatment or prevention of osteoporosis and abnormal bone mass conditions. ParticularMonascusstrains yield fermentation products with the desired biological activities.
REFERENCES:
patent: 3983140 (1976-09-01), Endo et al.
patent: 4031250 (1977-06-01), Haas et al.
patent: 4049495 (1977-09-01), Endo et al.
patent: 4137322 (1979-01-01), Endo et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4294846 (1981-10-01), Albers-Schonberg et al.
patent: 4294926 (1981-10-01), Monaghan et al.
patent: 4319039 (1982-03-01), Albers-Schonberg et al.
patent: 4342767 (1982-08-01), Albers-Schonberg et al.
patent: 4420491 (1983-12-01), Albers-Schonberg et al.
patent: 5362638 (1994-11-01), Dahiya
patent: 5627068 (1997-05-01), Kujumdzieva et al.
patent: 5712130 (1998-01-01), Hajko et al.
patent: 6046022 (2000-04-01), Zhang et al.
patent: 6410521 (2002-06-01), Mundy et al.
patent: 2006/0078533 (2006-04-01), Omoigui
patent: 1075875 (1993-09-01), None
patent: 1106230 (1995-08-01), None
patent: 1110560 (1995-10-01), None
patent: 1155421 (1997-07-01), None
patent: 1173361 (1998-02-01), None
patent: 3006216 (1980-02-01), None
patent: 3051175 (1980-02-01), None
patent: 2046737 (1980-02-01), None
patent: 2055100 (1980-07-01), None
patent: 55-150898 (1980-11-01), None
patent: 58-43783 (1983-03-01), None
patent: 62-132878 (1987-06-01), None
patent: 63-198973 (1988-08-01), None
patent: WO-99/23966 (1999-05-01), None
Wang et al. (English Abstract). Oct. 1995., Journal of the Formosan Medical Association=Taiwan yi zhi, vol. 94, No. 10, pp. 589-592.
Demain, et al., Manual of Industrial Microbiology and Biotechnology, American Society for Microbiology, 1986, pp. 66-83 and 87.
Yan, Z., et al. (1999) Effects of xuezhikang on blood lipids and lipoprotein concentrations of rabbits and quails with hyperlipideaemia. Chinese Pharmaceutical Journal, 30(11):656-660.
Han, M., et al. (1994) Experimental study on the decholesterolization of metabolites from monascus rubber. Microbiology, 21(5):279-280.
Read, B.E. and Liu, J.C. (1927), Chinese Medicinal Plants from the Pen Ts'ao Kang Mu, 3rdedition, published by Peking National History Bulletin.
T'ien-Kung K'ai-Wu chinese technology in the seventeenth century, translated by E-tu Zen Sun and Shiou-Chuan Sun, The Pennsylvania State University Press pp. 291-294, 1966.
Fielding, B.C., et al. (1961), The chemistry of fungi. part XXXIX. The structure of monascin. J. Chem. Soc. 4579-4589.
Broder, C.U. and Koehler, P.E. (1980) Pigments produced by monascus purpureus with regard to quality and quantity. J. Food Sci. 45:567-469.
Wong H. and Bau, Y. (1977) Pigmentation and antibacterial activity of fast neutron- and x-ray- induced strains of monascus purpureus went. Plant Physiol, 60:578-581.
Feling, P. and Wahren, J. (1975) Fuel homeostasis in exercise. N. Eng. J. Med. 293:1078-1084.
Grundy, S.M. (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New Eng. J. Med. 319:24-33.
Endo, A., (1976) New inhibitors of cholesterogenesis produced by penicillium citrinum. J. Antibiotics, 29:1346-1348.
Tsujita, Y., et al. (1979) Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase. Atherosclerosis 32:307-313.
Endo, A. (1979) Monacolin K, a new hypo-Cholesterlemic agent produced by a monascus species. J. Antibiotics 32:852-854.
Endo, A. (1980) Monacolin K, a new hypto-cholesterolemic agent the specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase. J. Antibiotics 33:334-336.
Tobert, J.A., et al. (1982) Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J. Clin Invest. 69:913-919.
Tobert, J.A. (1988) Effecacy and long-term adverse effect of lovastatin. Am J. Cardiol. 62:28J-34J.
The Merck Manual of Diagnosis and Therapty (1992) 16thedition, pp. 1044-1046.
Pi-Sunyer, F.X. (1991) Health implications of obesity. Am J. Clin Nutr. 53:1595S-1603S.
Dalin He
Liang Zhang Mao
Shuren Guo
Wen Duan Zhen
Xiu Peng Chi
Beijing Peking University WBL Corporation Ltd.
Fish & Richardson P.C.
Gitomer Ralph
Srivastava Kailash C.
LandOfFree
Method of treatment of osteoporosis with compositions of red... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of osteoporosis with compositions of red..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of osteoporosis with compositions of red... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3742972